Abstract
TNF-α is a pleiotropic cytokine with strong proinflammatory and immunomodulatory properties. TNF-α plays a critical role in many acute or chronic inflammatory diseases and anti-TNFstrategies have proven to be clinically effective. Two TNF-specific cell surface receptors TNF-R1 and TNF-R2 have been identified and the function of these receptors and the downstream intracellular signal transduction pathways have been extensively studied in vitro. For a long time TNF-R1 was considered to be the predominant mediator of TNF-signaling, whereas TNF-R2 was ascribed only auxilliary function. However, there is increasing clinical and experimental evidence for an important independent role of p80 signaling in chronic inflammatory conditions. It is conceivable that the multiple TNF-mediated chronic inflammatory disorders differ in terms of the ligand form (soluble TNF-α versus membrane bound TNF-α), the receptor (TNF-R1 versus TNF-R2) and the downstream signaling cascades utilized. The elucidation of the specific characteristics of TNF-signaling in distinct inflammatory disorders will lead to a better understanding ot the pathogenesis of these diseases and will be the basis for the development of more specific and more efficient therapeutic approaches.
Keywords: tnf, tnf-r2, signal transduction, inflammatory disorders
Current Molecular Medicine
Title: Differential TNF-Signaling in Chronic Inflammatory Disorders
Volume: 4 Issue: 4
Author(s): Martin H. Holtmann and Markus F. Neurath
Affiliation:
Keywords: tnf, tnf-r2, signal transduction, inflammatory disorders
Abstract: TNF-α is a pleiotropic cytokine with strong proinflammatory and immunomodulatory properties. TNF-α plays a critical role in many acute or chronic inflammatory diseases and anti-TNFstrategies have proven to be clinically effective. Two TNF-specific cell surface receptors TNF-R1 and TNF-R2 have been identified and the function of these receptors and the downstream intracellular signal transduction pathways have been extensively studied in vitro. For a long time TNF-R1 was considered to be the predominant mediator of TNF-signaling, whereas TNF-R2 was ascribed only auxilliary function. However, there is increasing clinical and experimental evidence for an important independent role of p80 signaling in chronic inflammatory conditions. It is conceivable that the multiple TNF-mediated chronic inflammatory disorders differ in terms of the ligand form (soluble TNF-α versus membrane bound TNF-α), the receptor (TNF-R1 versus TNF-R2) and the downstream signaling cascades utilized. The elucidation of the specific characteristics of TNF-signaling in distinct inflammatory disorders will lead to a better understanding ot the pathogenesis of these diseases and will be the basis for the development of more specific and more efficient therapeutic approaches.
Export Options
About this article
Cite this article as:
Holtmann H. Martin and Neurath F. Markus, Differential TNF-Signaling in Chronic Inflammatory Disorders, Current Molecular Medicine 2004; 4 (4) . https://dx.doi.org/10.2174/1566524043360636
DOI https://dx.doi.org/10.2174/1566524043360636 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery Identification of Candidate Genetic Markers and a Novel 4-genes Diagnostic Model in Osteoarthritis through Integrating Multiple Microarray Data
Combinatorial Chemistry & High Throughput Screening Natural Antibodies in Murine Atherosclerosis
Current Drug Targets Radix Paeoniae Rubra Ameliorates Lupus Nephritis in Lupus-Like Symptoms of Mrl Mice by Reducing Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and Platelet Endothelial Cell Adhesion Molecule-1 Expression
Combinatorial Chemistry & High Throughput Screening Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy Editorial [Hot topic: Innate Immunity Molecules S100A8/A9 Involved in Stress Response and Cancer Biology (Guest Editors: Claus Kerkhoff and Saeid Ghavami)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy An in silico Workflow that Yields Experimentally Comparable Inhibitors for Human Dihydroorotate Dehydrogenase
Current Computer-Aided Drug Design Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Effect of Thermal and Shear Stressors on the Physical Properties, Structural Integrity and Biological Activity of the Anti-TNF-alpha Monoclonal Antibody, Infliximab
Current Pharmaceutical Biotechnology Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review
Inflammation & Allergy - Drug Targets (Discontinued) Computation-Based Design and Engineering of Protein and Antibody Therapeutics
Drug Design Reviews - Online (Discontinued) TNF-α and IL-6: The Link between Immune and Bone System
Current Drug Targets Local Delivery of Therapeutics for Percutaneous Coronary Intervention
Current Drug Delivery Mouse Models of Primary Biliary Cirrhosis
Current Pharmaceutical Design Modulators of Protein-Protein Interactions – Novel Approaches in Targeting Protein Kinases and Other Pharmaceutically Relevant Biomolecules
Current Topics in Medicinal Chemistry High-density Lipoprotein (HDL) Dysfunction and the Future of HDL
Current Vascular Pharmacology